Drug Trial Radar · NCT00333944
Study to Know the Efficacy of Higher Doses of Pralidoxime in Patients of Organophpsphorus Poisoning.
Last checked: Nov 19, 2026Latest source record: Jun 6, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
May 2000
Primary completion
Not stated
Study completion Jun 2003
Sponsor
- Lead sponsor
- Giriraj HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 6, 2006
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether high doses of pralidoxime(PAM) are effective as compare to lower doses of PAM in the management of moderately sever organophosphorus poisoning patients.
Conditions
- Acute Organophosphorus Pesticide Poisoning
Interventions
Pralidoxime(drug)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median atropine dose required in first 24 hours
- proportion of patients who required intubation or developed intermediate syndrome
- number of days ventilated and required ICU care
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Giriraj Hospital and Intensive Care Unit.
Baramati. Pune District., Maharashtra, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.